Peptris Technologies & Revio Therapeutics Partners for AI-Discovered Drug Candidate
The drug, in the preclinical stage, targets DMD, a rare genetic disorder primarily affecting boys and causing progressive muscle degeneration.
Peptris Technologies, an AI-powered drug discovery startup, has entered into a licensing agreement with US-based Revio Therapeutics to advance the development of its AI-discovered drug candidate, PEPR124 (RT001).
The drug, in the preclinical stage, targets Duchenne Muscular Dystrophy (DMD), a rare genetic disorder primarily affecting boys and causing progressive muscle degeneration.
The terms of the agreement include a licensing deal for PEPR124 (RT001) to Revio Therapeutics for further development in global markets, except in BRICS countries, where Peptris retains commercialization rights.
Strengthening India’s Position in AI-Driven Drug Discovery
Peptris Technologies' breakthrough in AI-powered drug discovery is significant for India’s position in the global biotech landscape. The company’s proprietary platform was instrumental in discovering PEPR124 (RT001), a mutation-agnostic and safe therapeutic candidate that has shown promise in preclinical studies.
This achievement highlights India’s growing contribution to AI-driven drug discovery, with the agreement reflecting global confidence in the potential of AI to address unmet medical needs.
Duchenne Muscular Dystrophy, a genetic disorder with limited treatment options, represents a major unmet need in healthcare.
The global DMD market is valued at over $3 billion, underscoring the significant demand for effective therapies.
As a repurposed therapeutic, PEPR124 (RT001) offers a new avenue of treatment that could change the landscape for patients with DMD, particularly given its demonstrated safety profile and mutation-agnostic nature.
